※一部利用できない機能があります
| 1.
図書 |
図書
|
里見清一著
|
||||
| 2.
図書 |
図書
|
國頭英夫, 佐藤恵子, 吉村健一著
|
||||
| 3.
論文 |
論文
|
Oka, Rie ; Nomura, Akihiro ; Yasugi, Ayaka ; Kometani, Mitsuhiro ; Gondoh, Yuko ; Yoshimura, Kenichi ; Yoneda, Takashi ; 大家, 理恵 ; 野村, 章洋 ; 米谷, 充弘 ; 吉村, 健一 ; 米田, 隆
概要:
金沢大学附属病院代謝内科<br />Nutritional intervention is effective in improving glycemic control in patients with type 2 diabetes b
…
ut requires large inputs of manpower. Recent improvements in photo analysis technology facilitated by artificial intelligence (AI) and remote communication technologies have enabled automated evaluations of nutrient intakes. AI- and mobile-supported nutritional intervention is expected to be an alternative approach to conventional in-person nutritional intervention, but with less human resources, although supporting evidence is not yet complete. The aim of this study is to test the hypothesis that AI-supported nutritional intervention is as efficacious as the in-person, face-to-face method in terms of improving glycemic control in patients with type 2 diabetes.
続きを見る
|
||||
| 4.
論文 |
論文
|
Wakabayashi, Yusuke ; Oka, Rie ; Nakaya, Masako ; Karashima, Shigehiro ; Kometani, Mitsuhiro ; Sakurai, Masaru ; Yoshimura, Kenichi ; Yoneda, Takashi ; 大家, 理恵 ; 唐島, 成宙 ; 米谷, 充弘 ; 櫻井, 勝 ; 吉村, 健一 ; 米田, 隆
概要:
金沢大学附属病院代謝内科<br />Objective. Individuals with multiple metabolic risk factors often experience concomitant sleep-disorde
…
red breathing (SDB). We aimed to determine the associations of SDB with individual components of metabolic syndrome independent of obesity. Methods. A cross-sectional study was conducted in 1137 employees aged 30–64 years. Apnea-hypopnea index (AHI) was assessed using a portable monitor for obstructive sleep apnea by admission. Of these, 451 participants took an oral glucose tolerance test to assess homeostatic model assessment of insulin resistance (HOMA-IR) and Matsuda insulin sensitivity index (ISI). Results. The odds ratio (OR) of the highest category of the AHI (≥15 episodes per hour) compared to the lowest one (<5 episodes per hour) was significantly elevated for hypertension, for hypertriglyceridemia, and for low HDL-cholesterolemia when adjusted for age, sex, and alcohol and smoking status (). After further adjustment for body mass index (BMI) or waist circumference, the associations for hypertension still remained statistically significant () while those for hypertriglyceridemia and low HDL-cholesterolemia were no longer significant. The association between higher insulin resistance as assessed by HOMA-IR and Matsuda ISI and higher categories of the AHI was also lost after adjustment for BMI. Conclusion. Obesity was a strong confounding factor in the association between SDB and most metabolic risk factors including insulin resistance, except for hypertension. Further longitudinal study is needed to examine the temporal or causal relationships between SDB and metabolic risk factors. This trial is registered with UMIN-CTR UMIN000028067.
続きを見る
|
||||
| 5.
論文 |
論文
|
5. Insulin Secretion and Risk for Future Diabetes in Subjects with a Nonpositive Insulinogenic Index
Aono, Daisuke ; Oka, Rie ; Kometani, Mitsuhiro ; Takeda, Yoshimichi ; Karashima, Shigehiro ; Yoshimura, Kenichi ; Takeda, Yoshiyu ; Yoneda, Takashi ; 青野, 大輔 ; 大家, 理恵 ; 米谷, 充弘 ; 武田, 仁裕 ; 唐島, 成宙 ; 吉村, 健一 ; 武田, 仁勇 ; 米田, 隆
概要:
金沢大学附属病院代謝内科<br />Aim. To characterize subjects with a nonpositive insulinogenic index and longitudinally observe change
…
s in their glucose tolerance. Subjects and Methods. A historical cohort study was conducted using data from the medical checkups of public school workers. Indices of insulin secretion and insulin sensitivity derived from oral glucose tolerance test (OGTT) and the incidences of diabetes and impaired glucose tolerance (IGT) were compared among subgroups of subjects with different insulinogenic index (change in insulin/change in glucose over the first 30 min on the OGTT). Results. Of the 1464 nondiabetic subjects at baseline, 72 (4.9%) subjects had a nonpositive insulinogenic index: 42 of those subjects had a nonpositive glucose response (ΔGlu0–30 ≤ 0) and 30 had a nonpositive insulin response (ΔIns0–30 ≤ 0). Compared with subjects who had normal glucose tolerance (NGT) with insulinogenic index ≥ 0.4, subjects with a nonpositive glucose response had a higher first-phase Stumvoll and lower incidences of diabetes and IGT based on a log-rank test (), whereas subjects with a nonpositive insulin response had lower indices of insulin secretion and a higher incidence of diabetes (). Conclusions. These results demonstrate that in the first 30 min on the OGTT, subjects with a nonpositive insulinogenic index due to a nonpositive glucose response (ΔGlu0–30 ≤ 0) had a lower risk for future diabetes and that subjects with nonpositive insulin response (ΔIns0–30 ≤ 0) had a higher risk for future one.
続きを見る
|
||||
| 6.
論文 |
論文
|
Wakisaka, Naohiro ; Endo, Kazuhira ; Kitazawa, Tomohiro ; Shimode, Yuzo ; Kato, Koroku ; Moriyama-Kita, Makiko ; Koda, Wataru ; Ikeda, Hiroko ; Ishikawa, Kazuya ; Ueno, Takayoshi ; Nakanishi, Yosuke ; Kondo, Satoru ; Sugimoto, Hisashi ; Yoshimura, Kenichi ; Tsujii, Hiroyuki ; Kawashiri, Shuichi ; Omoto, Kiyoshi ; Yoshizaki, Tomokazu ; 脇坂, 尚宏 ; 遠藤, 一平 ; 加藤, 広禄 ; 喜多, 万紀子 ; 香田, 渉 ; 池田, 博子 ; 石川, 和也 ; 上野, 貴雄 ; 中西, 庸介 ; 近藤, 悟 ; 杉本, 寿史 ; 吉村, 健一 ; 川尻, 秀一 ; 吉崎, 智一
概要:
金沢大学医薬保健研究域医学系<br />Background: In sentinel lymph node (SLN) biopsy for head and neck cancers, the radioisotope method h
…
as been the gold standard. However, this method has several problems, such as unavoidable radiation exposure and requirements of expensive equipment. Aims/Objectives: To overcome these problems, we evaluated the contrast-enhanced ultrasonography (CEUS)-guided SLN-detection method, and predicted the SLN metastatic status using novel ultrasound technology, superb microvascular imaging (SMI). Methods: Ten patients (6 with oral and 4 with oropharyngeal cancers) without neck lymph node metastasis were enrolled in this study. Ultrasound contrast agent, Sonazoid ™ , was infiltrated into the mucosa at the primary site to observe the lymphatic ducts and SLNs in the neck field. The detected SLNs were examined for blood flow using SMI to categorize the SLNs metastases-positive or negative. Results: SLNs were successfully detected in 8 out of 10 cases. In 7 out of the 8 cases, in whom SLNs were successfully detected, the metastatic status of SLNs was correctly diagnosed with SMI. Conclusions and significance: Although more clinical data are needed based on a larger cohort, establishing the CEUS-guided SLN-detection and criteria for the accurate diagnosis of SLN-metastases using SMI would be valuable as an alternative to radioisotope method, in oral and oropharyngeal cancers. © 2019, © 2019 Acta Oto-Laryngologica AB (Ltd).<br />Embargo Period 12 months<br /># This study was approved by the Bioethics Committee of Kanazawa University (Nos.2016-037 and 2017-015). The clinical study protocol was explained in detail to patients eligible for the study. Written consent was obtained from all patients who agreed to participate.# This work was supported by a grant-in-aid from The Public Trust Fund For Clinical Cancer Research.
続きを見る
|
||||
| 7.
論文 |
論文
|
Takeuchi, Shinji ; Murayama, Toshinori ; Yoshimura, Kenichi ; Kawakami, Takahiro ; Takahara, Shizuko ; Imai, Yasuhito ; Kuribayashi, Yoshikazu ; Nagase, Katsuhiko ; Goto, Koichi ; Nishio, Makoto ; Hasegawa, Yoshinori ; Satouchi, Miyako ; Kiura, Katsuyuki ; Seto, Takashi ; Yano, Seiji ; 竹内, 伸司 ; 村山, 敏典 ; 吉村, 健一 ; 川上, 貴裕 ; 髙原, 志津子 ; 今井, 康人 ; 栗林, 義和 ; 長瀬, 克彦 ; 矢野, 聖二
概要:
金沢大学附属病院がんセンター<br />Background: The rearranged during transfection (RET) fusion gene was discovered as a driver on-cogen
…
e in 1-2% of non-small cell lung cancers (NSCLCs). Alectinib is an approved anaplastic lymphoma kinase (ALK) inhibitor that may also be effective for RET fusion-positive NSCLC. Methods/Design: RET fusion-positive NSCLC patients treated with at least one regimen of chemotherapy are being recruited. In step 1, alectinib (600 or 450 mg, twice daily) will be administered following a 3+3 design. The primary endpoint is safety. In step 2, alectinib will be administered at the recommended dose (RD) defined by step 1. The primary endpoint is the response rate of RET inhibitor treatment-naïve patients. Conclusion: This is the first study to investigate the safety and preliminary efficacy of alectinib in RET fusion-positive NSCLC patients. If successful, alectinib treatment may lead to substantial and important changes in the management of NSCLC with RET fusion genes. © 2017, University of Tokushima. All rights reserved.
続きを見る
|
||||
| 8.
論文 |
論文
|
Oka, Rie ; Shibata, Kyoko ; Sakurai, Masaru ; Kometani, Mitsuhiro ; Yamagishi, Masakazu ; Yoshimura, Kenichi ; Yoneda, Takashi ; 大家, 理恵 ; 柴田, 恭子 ; 櫻井, 勝 ; 米谷, 充弘 ; 山岸, 正和 ; 吉村, 健一 ; 米田, 隆
概要:
金沢大学附属病院研修医・専門医総合教育センター<br />We aimed to clarify how the trajectories of 1-hour postload plasma glucose (PG) and 2-hour
…
PG were different in the development of type 2 diabetes. Using data of repeated health checkups in Japanese workers from April 2006 to March 2016, longitudinal changes of fasting, 1-hour, and 2-hour PG on the oral glucose tolerance test were analyzed with a linear mixed effects model. Of the 1464 nondiabetic subjects at baseline, 112 subjects progressed to type 2 diabetes during the observation period (progressors). In progressors, 1-hour PG and 2-hour PG showed gradual increases with slopes of 1.33 ± 0.2 and 0.58 ± 0.2 mg/dL/year, respectively, followed by a steep increase by which they attained diabetes. Until immediately before the diabetes transition, age- and sex-adjusted mean level of 2-hour PG was 149 ± 2.7 mg/dL, 34 ± 2.7 (30%) higher compared to nonprogressors, while that of 1-hour PG was 206 ± 4.1 mg/dL, 60 ± 4.3 mg/dL (41%) higher compared to nonprogressors. In conclusion, diabetes transition was preceded by a mild elevation of 2-hour PG for several years or more. The elevation in 1-hour PG was larger than that of 2-hour PG until immediately before the transition to diabetes. © 2017 Rie Oka et al.<br />Embargo Period 12 months
続きを見る
|
||||
| 9.
論文 |
論文
|
吉村, 健一 ; Yoshimura, Kenichi
概要:
金沢大学附属病院<br />本研究の主たる目的は、臨床研究において逐次的に実施される治療法を評価したい状況に対して、一連の治療法及び個々の治療法の評価について新規推定法を開発することにあった。既存の推定法では、強いモデルの仮定を要するが、開
…
発した推定量ではそのような制約を受けない。臨床研究における典型的な設定を想定した上でシミュレーションによって評価を行い、従来法の限界でもあったモデルの仮定に対してもロバストであり、良好な結果を示すことができた。<br />The purpose of this study was to develop a new inferential method for the evaluation of effect of a series of treatments or a treatment in the setting of sequential intervention in clinical studies. Existing estimation methods require strong assumptions based on a statistical model in general, but a newly proposed estimator are not subject to such restrictions. The simulation study was performed under a typical setting in clinical studies, and it was robust against the assumption of the statistical model, which was the limit of the conventional method.<br />研究課題/領域番号:16K16017, 研究期間(年度):2016-04-01 – 2020-03-31<br />出典：「逐次治療の評価における重み付き並び替え法を用いた新規推定法の開発」研究成果報告書 課題番号16K16017（KAKEN：科学研究費助成事業データベース（国立情報学研究所））（https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-16K16017/16K16017seika/)を加工して作成
続きを見る
|
||||
| 10.
電子ブック |
ＥＢ
|
里見清一著
|
